Retroactive Analysis: Applying The 25-Gate Framework To 10 Years Of Longevity Biotech (Hypothetical)

March 3, 2026

This is not investment advice. I am not a licensed investment advisor. This entire article describes a hypothetical paper exercise conducted retroactively for educational purposes. No real money was invested. No securities transactions occurred. Hypothetical results carry inherent limitations. They are designed with the benefit of hindsight, do not represent actual trading, and may not account for market factors like lack of liquidity (CFTC Rule 4.41). These hypothetical results are based on private-round entries inaccessible to non-accredited investors. Approximately 95% of the hypothetical entries modeled here involve early-stage private rounds that are legally restricted to accredited investors under SEC Rule 501 of Regulation D, requiring annual income exceeding $200,000 ($300,000 jointly) or net worth exceeding $1 million (excluding primary residence). Even qualifying investors may not have had access due to minimum check sizes, allocation caps, and existing investor relationships. The ~4.2x hypothetical return is not representative of typical results. The majority of early-stage biotech startups result in a 100% loss of capital. Consult a licensed financial professional before making any investment decision. Full legal terms below.

An estimated 4.2x hypothetical return on $2.5 million in paper capital. Roughly $10.5 million in hypothetical value. An estimated $8.0 million in hypothetical paper gains. 17 companies out of 411 screened made the cut. Two losses (one total, one partial). Four verified exits via acquisition. Three went public via IPO and are still held. No real money was invested at any point.

Those numbers are honest. And they come with ranges, because this is early-stage biotech and precision where none exists would be a lie.

The conservative floor is 3.3x. The optimistic ceiling is 5.5x. The midpoint, which I think is closest to reality, is roughly 4.2x. Every number in this article is tagged with its source and confidence level. Where I'm estimating, I'll tell you. Where the data is verified, I'll tell you that too.

I spent 24 years running CuraDebt, a financial services company I built from scratch to an A+ BBB rating and over 1,600 five-star reviews. I sold part of the company last month. For 24 years I watched people struggle with money. Save. Invest. Try to build something that lasts. And somewhere in that process I started asking a different question. What's the point of wealth if your body gives out at 72?

That question led me here. To longevity biotech. To the companies developing therapeutics that target why we age. And to this exercise, applying a systematic framework to every longevity company I could find going back to 2015, and seeing what the data says.

I screened 411 longevity companies across 10 years (2015 through February 2026) through a 25-gate evaluation framework. 360 therapeutic companies went through the full scoring system. 51 infrastructure companies were evaluated under a separate L-45 classification.

The first gate filters for companies developing therapeutics that directly target at least one core mechanism of biological aging, even if aging isn't on the label. A cardiovascular gene editing company whose mechanism addresses an aging hallmark? That passes. A GLP-1 metabolic platform that intersects four aging pathways at once? That passes too. Supplements, diagnostics, devices, holding companies, those get filtered before scoring starts.

Beyond that, the framework scores for translatable science, strong founders, real IP, clear regulatory path, pre-defined kill switches, and something I put a lot of weight on, how acquirable is this company to Big Pharma?

Companies scoring 4.0+ go into Tier 1 ($125K each). Scoring 3.8-3.9 goes into Tier 2 ($200K each). Everything else goes to a watch list or gets excluded. These scores are part of a retroactive hypothetical exercise. They are not buy recommendations.

$2.5 million in hypothetical capital. Twelve Tier 1 at $125K = $1.5M. Five Tier 2 at $200K = $1.0M. No follow-on investments.

Evaluation timing. Every company was scored based on data available at the time of the hypothetical entry round, not with hindsight. If the entry is modeled at Series A in 2017, the scoring reflects what was knowable in 2017.

This section exists because intellectual honesty requires it.

The 25-Gate Framework was developed and refined over a period during which I had access to the outcomes of the companies it evaluates. The framework's ability to "select" the 17 companies in this portfolio and "exclude" the 14 vetoed companies is a result of historical alignment between the framework's criteria and the data it was built from. It is not predictive proof.

In plain terms: I built the scoring system while already knowing which companies succeeded and which failed. The gates, weights, and thresholds were calibrated against real outcomes. This is backtesting. The standard limitations of backtesting apply:

I am publishing this exercise because I believe the framework's structure and logic have educational value. But the returns described here are a product of retroactive analysis, not a track record. Readers should treat them accordingly.

To put the selection rate in context:

411 companies entered the screening process. 394 were excluded. 17 made it through. That is a 4.1% pass rate.

The framework is designed to say no. 95.9% of companies evaluated did not pass. Whether that selectivity would perform the same way on the next 411 companies is unknown.

Disclosure: I personally hold equity in Yuva Biosciences and Repair Biotechnologies, neither of which is in the hypothetical portfolio. This exercise remains hypothetical, but readers should be aware of the potential for bias in my analysis of companies I hold.

Confidence tags throughout:

✅ = Verified to a press release, SEC filing, or exchange price.

⚠️ = Estimated from partial data. Valuations marked ⚠️ are implied from last-known private funding rounds. They do not account for liquidation preferences, participation rights, or transaction costs. In practice, early-stage common equity holders often receive less than implied ownership percentages suggest, because later-stage institutional investors typically hold senior liquidation preferences. The hypothetical MOIC figures assume common stock parity, which overstates the likely return for a Series A participant in most real-world exit scenarios.

1. Carmot Therapeutics - EXITED (Roche Acquisition) Score: 4.4 | GLP-1/GIP dual agonism (metabolic aging)

Entry: ~2016, Series A era. Framework basis (2016 data): GLP-1/GIP mechanism validated by Lilly's dulaglutide, Column Group backing, Stanford chemistry IP. Raised ~$371M across Series A-E before acquisition. ✅

Exit: Roche, $2.7B upfront + $400M milestones. Dec 2023. ✅

$125K in, ~0.71% at ~$17.5M ⚠️, ~85-90% dilution through 5+ rounds, $1.9M-$2.9M estimated exit value. MOIC: 15-23x ⚠️

2. Verve Therapeutics - EXITED (Lilly Acquisition) Score: 4.2 | Base editing (PCSK9 gene silencing for cardiovascular aging)

Entry: May 2019, Series A ($58.5M). Framework basis (Q1 2019 data): PCSK9 base editing with preclinical proof, Beam collaboration, Sekar Kathiresan from the Broad Institute. IPO'd Jun 2021 at $19/share. ✅

Exit: Lilly, $10.50/share (~$1.0B) + $3.00 CVR. Jun 2025. ✅

$125K in, ~0.17% at ~$75M ⚠️, ~60-70% dilution, $500K-$670K ⚠️ (+ CVR). MOIC: 4-5x ⚠️

3. Vividion Therapeutics - EXITED (Bayer Acquisition) Score: 4.1 | Covalent chemical proteomics (drugging "undruggable" targets)

Entry: Feb 2017, Series A ($50M). Framework basis (early 2017 data): Scripps Research platform from Ben Cravatt's lab, ARCH + Versant backing. Raised ~$271M total. $101M Celgene collaboration in 2018. ✅

Exit: Bayer, $1.5B upfront + $500M milestones. Aug 2021. ✅

$125K in, ~0.25% at $50M ⚠️, ~50-60% dilution, $1.5M-$1.9M ⚠️. MOIC: 12-15x ⚠️

4. Alkahest - EXITED (Grifols Acquisition) Score: 4.0 | Plasma-derived aging factors (GDF11, young blood research)

Entry: ~2015. Framework basis (2015 data): Tony Wyss-Coray's Stanford parabiosis research (Nature, 2014), Grifols strategic partnership. Entry valuation ~$83M implied (Grifols bought 45% for $37.5M). ⚠️

Exit: Grifols acquired remaining ~52% for $146M. Total value ~$279M. Sep 2020. ✅

$125K in, ~0.15% at $83M ⚠️, ~30-40% dilution, $250K-$300K ⚠️. MOIC: 2.0-2.4x ⚠️

5. Insilico Medicine - PUBLIC (HKEX: 3696) Score: 4.0 | AI-driven drug discovery targeting aging-related fibrosis

Entry: Jun 2018, Series A ($6M, WuXi-led). Framework basis (mid-2018 data): GAN-based molecule design was new to the field, Alex Zhavoronkov had published extensively on AI and aging, no AI-discovered drug had entered clinical trials anywhere. Raised $500M+ pre-IPO. ✅

IPO: Dec 30, 2025 at HKD 24.05/share. Raised ~$293M. Largest HK biotech IPO of 2025. ✅

Volatility note: This stock traded from HKD 24.05 at IPO to a 52-week high of HKD 80.90 and back to ~HKD 61, all within two months of listing. This is typical for newly listed biotech with limited float. Any MOIC stated here is a snapshot.

Current: ~HKD 61-62 (Feb 27). 52-week range: 29.98-80.90. ✅

No sell triggers fired. Lead program ISM001-055 (IPF) in Phase 2. Position held.

$125K in, ~0.42% at ~$30M ⚠️, ~88-93% dilution, $1.3M-$2.2M ⚠️. MOIC: 11-18x (snapshot) ⚠️

6. BioAge Labs - PUBLIC (NASDAQ: BIOA) Score: 4.0 | Metabolic aging platform, pivoted to NLRP3 inhibition (BGE-102)

Entry: Jul 2017, Series A ($10.9M). Framework basis (mid-2017 data): mining human aging datasets for drug targets was novel, Kristen Fortney had published on computational aging biology. IPO'd Sep 2024 at $18/share. ✅

Lead program azelaprag failed Phase 2 (Nov 2024). That triggered a full exit signal under Gate 25. BioAge met all four criteria of the Pivot Re-Evaluation Protocol (defined in the Monitoring Framework section below). The protocol applied, and the position was held at 50%. Both the strict-exit and pivot-hold interpretations are shown in the return math. See the Monitoring Framework section for the full protocol definition.

Current: ~$20-$23 range (Feb 27). 52-week range: $2.88-$24.00. ✅

$125K in, 50% sold at crash (~$4/share), 50% held, total value $185K-$385K ⚠️. MOIC: 1.5-3.1x (pivot hold) or 0.6-1.0x (strict exit) ⚠️

7. Denali Therapeutics - PUBLIC (NASDAQ: DNLI) Score: 4.0 | Blood-brain barrier crossing therapeutics (neurodegeneration / brain aging)

Entry: ~2016, pre-IPO. Framework basis (2016 data): TransportVehicle platform for crossing the blood-brain barrier, Ryan Watts (ex-Genentech), $217M mega-round. IPO'd Dec 2017 at $18/share. ✅

Tividenofusp alfa (DNL310) for Hunter Syndrome is under FDA Priority Review. PDUFA date: April 5, 2026. This is a binary regulatory event. Approval or rejection could produce significant price movement in either direction.

Current: ~$21.50 (Feb 27). Market cap $3.4-3.5B. Analyst consensus: Buy, avg PT $30.80. ✅

No sell triggers fired. $1.5B+ cash. Position held.

$125K in, ~0.08% at ~$150M ⚠️, ~60-75% dilution, $680K-$1.0M ⚠️. MOIC: 5.4-8.2x ⚠️

8. Maxwell Biosciences - ACTIVE PRIVATE (Pre-IND) Score: 4.1 | Synthetic antimicrobial peptoids (Claromers), immunosenescence

Entry: Mar 2022, Seed ($10.8M). Framework basis (early 2022 data): Claromers with broad-spectrum activity against drug-resistant pathogens, DARPA/DOD interest, founder J. Scotch McClure with deep biodefense expertise. ✅

Since entry: Completed NHP study (safety + efficacy against two pathogens, single treatment). 7 signed US military agreements across USAMRIID, Naval NIDDL, USAISR, WRAIR, MTEC, and NMRC DAID. Written Pre-IND feedback from FDA. $63M+ in non-dilutive government funding. ✅

Total equity raised: ~$30.8M. IND submission anticipated 2026.

$125K in, ~0.42% at ~$30M ⚠️, ~25-35% dilution, $160K-$250K ⚠️. MOIC: 1.3-2.0x ⚠️

⚠️ Private. Illiquid. No market for these shares. Value is theoretical until an exit.

9. Halia Therapeutics - ACTIVE PRIVATE (Phase 2a) Score: 4.0 | NLRP3 inflammasome inhibitor (inflammaging)

Entry: ~2020, pre-Series A. Framework basis (2020 data): NLRP3 inhibition for inflammaging gaining validation, novel chemistry. Series C $30M (Jan 2024). ✅

Current status: Phase 2a in MDS (ofirnoflast). Data at ASH 2025.

$125K in, ~0.63% at ~$20M ⚠️, ~50-60% dilution, $250K-$470K ⚠️. MOIC: 2.0-3.8x ⚠️

⚠️ Private. Illiquid. No market for these shares.

10. Turn.bio - ACTIVE PRIVATE Score: 4.0 | mRNA-based epigenetic reprogramming

Entry: ~2021, Seed (~$5M, Khosla Ventures). Framework basis (2021 data): mRNA-based partial reprogramming without dedifferentiation, Khosla backing.

HanAll Biopharma licensed the platform (up to $300M, 2024). Klotho Neurosciences signed an LOI to acquire Turn.bio on Sep 30, 2025. LOI expired Oct 7. Board determined the deal did not fit their long-term strategic plan. Acquisition never closed. ✅

$125K in, ~0.63% at ~$20M ⚠️, ~35-45% dilution, $140K-$325K ⚠️. MOIC: 1.1-2.6x ⚠️

⚠️ Private. Illiquid. Status uncertain after failed LOI.

11. Navitor Pharmaceuticals - ACTIVE PRIVATE (Near-Loss) Score: 4.0 | Selective mTORC1 inhibition (rapamycin pathway without immunosuppression)

Entry: ~2015, early round (Polaris Partners-led). Framework basis (2015 data): selective mTORC1 without immunosuppression. Scored 4.0, right at the Tier 1 floor. Selectivity was the concern even at entry. Total raised: $56-99M. ✅

NV-5138 Phase 2 failed. Anakuria Therapeutics spun out and was acquired by Janssen (Feb 2022) for partial value recovery.

$125K in, ~0.38% at ~$32.5M ⚠️, ~55-65% dilution, $40K-$100K ⚠️. MOIC: 0.3-0.8x ⚠️ - this is a loss

12. Rubedo Life Sciences - ACTIVE PRIVATE (Phase 1) Score: 4.0 | Precision senolytics via single-cell RNA sequencing

Entry: Dec 2020, Seed ($12M, Khosla-led). Framework basis (late 2020 data): precision senolytics using scRNA-seq, Khosla backing, published science on senescent cell heterogeneity. Series A $40M (Apr 2024). ✅

Current: Phase 1 (RLS-1496, dermatology).

$125K in, ~0.42% at ~$30M ⚠️, ~35-45% dilution, $275K-$490K ⚠️. MOIC: 2.2-3.9x ⚠️

⚠️ Private. Illiquid. No market for these shares.

13. Gordian Biotechnology - ACTIVE PRIVATE (Preclinical) Score: 3.9 | High-throughput in vivo screening for tissue-specific aging interventions

Entry: ~2022. Framework basis (2022 data): in vivo screening platform, Founders Fund + Longevity Fund. Total raised: $60M. ✅

OA and MASH screens complete. Pre-IND.

$200K in, ~0.67% at ~$30M ⚠️, ~50% dilution, $330K-$500K ⚠️. MOIC: 1.7-2.5x ⚠️

⚠️ Private. Illiquid. No market for these shares.

14. Cyclarity Therapeutics - ACTIVE PRIVATE (Phase 1, Australia) Score: 3.8 | Cyclodextrin-based removal of oxidized cholesterol (7-KC) from arteries

Formerly Underdog Pharmaceuticals. Entry: ~2020. Framework basis (2020 data): cyclodextrin approach to clearing 7-KC from arterial walls, Laura Deming / Longevity Fund. Series A Tranche 1 ~$6.4M (Jan 2025). ✅

Phase 1 in Australia (CMAX / Monash). Not FDA IND.

$200K in, ~1.33% at ~$15M ⚠️, ~25% dilution, $250K-$400K ⚠️. MOIC: 1.3-2.0x ⚠️

⚠️ Private. Illiquid. Value highly uncertain.

15. Amplifier Therapeutics - ACTIVE PRIVATE (Phase 1B, EU) Score: 3.8 | AMPK / mitochondrial pathway for cardiometabolic aging

Cambrian Bio pipeline company (Sweden). Entry: Oct 2023, Series A ($33.25M). Framework basis (Q4 2023 data): AMPK activation for cardiometabolic aging, RA Capital + Future Ventures, preclinical combo data with semaglutide. ✅

Phase 1B started (ATX-304, EU, overweight/prediabetic).

$200K in, ~0.20% at ~$100M ⚠️, minimal dilution, $260K-$400K ⚠️. MOIC: 1.3-2.0x ⚠️

⚠️ Private. Illiquid. No market for these shares.

16. Deciduous Therapeutics - ACTIVE PRIVATE (Preclinical) Score: 3.8 | iNKT cell-based senescent cell clearance

Entry: ~2021, Seed. Framework basis (2021 data): iNKT cells recognize senescent cells through a lipid-antigen pathway, different from CAR-T or CAR-NK. UCSF's Anil Bhushan, Laura Deming / Longevity Fund. ✅

Preclinical. Candidate nomination complete, safety studies underway.

$200K in, ~2.0% at ~$10M ⚠️, ~25-35% dilution, $195K-$375K ⚠️. MOIC: 1.0-1.9x ⚠️

⚠️ Private. Illiquid. Preclinical stage. Highest uncertainty in the portfolio.

17. Continuum Biosciences - DISSOLVED (Total Loss) Score: 3.8 | Mitochondrial uncouplers for NASH/obesity

Life Biosciences subsidiary (David Sinclair). Scored 3.8, right at the Tier 2 floor. Minimal capitalization. No clinical data. Entry ~2023.

Company permanently closed. Hypothetical loss: $200,000. The monitoring framework could not fire because there were no milestones to monitor.

DNLI, BIOA, and 3696.HK prices are as of the last trading day before Feb 28, 2026. They change daily. Nine companies remain private. Private positions are illiquid. There is no market for these shares. Paper gains are unrealized and theoretical until an exit occurs. Estimated values do not account for liquidation preferences, participation rights, or transaction costs.

76% of value comes from verified acquisitions or live public prices. 23% is in private companies with no secondary market, unrealizable until a future exit event.

Fourteen companies hit permanent exclusion. Single-pivotal-trial dependency or predatory dilution triggered the gates.

Unity Biotechnology, Phase 2 failed, equity near zero. resTORbio, Phase 3 failed, reverse merged, equity destroyed. Stealth BioTherapeutics, missed primary endpoint. Longeveron, IPO at $8, fell to $0.90. CohBar, wound down. AgeX Therapeutics, chronic dilution.

Those six alone would have destroyed serious hypothetical capital. As stated in the Methodology Bias section, I knew they failed before I built the gates. The veto gates were designed and applied after these outcomes were known. There is no guarantee these gates would catch similar failures in real time.

The largest hypothetical multiples came from Big Pharma acquisitions. Carmot to Roche ($2.7B, 15-23x). Vividion to Bayer ($1.5-2.0B, 12-15x). Verve to Lilly ($1.0-1.3B, 4-5x). Alkahest to Grifols ($279M, 2.0-2.4x).

The IPOs produced returns as well, but they are snapshots of live prices, not locked-in exits.

The structural focus was on companies that Big Pharma might need to acquire. That is where the largest hypothetical multiples came from. Whether that pattern holds going forward is unknown.

Most investment theses have one return: financial. You either make money or you don't. Longevity biotech has something different. If these companies succeed at what they are building, the return is not only financial. It is years.

Consider what these 17 companies are working on. Carmot built GLP-1/GIP agonists that target metabolic aging. Roche paid $2.7 billion for that science. Verve built one-time gene editing to silence PCSK9, potentially eliminating a leading driver of cardiovascular disease. Lilly paid over $1 billion. Denali is building therapeutics that cross the blood-brain barrier. Maxwell is developing synthetic antimicrobial peptoids that mimic the human immune system, backed by 7 US military research agreements. Halia targets the NLRP3 inflammasome. Rubedo is clearing senescent cells with precision.

These are potential medicines targeting the biology that determines how long you live and how well you function.

Researchers call it healthspan, the years you live in good health. The gap between lifespan and healthspan is about 9-12 years for most people. That gap is filled with cardiovascular disease, neurodegeneration, metabolic dysfunction, cancer, and frailty. Every company in this portfolio targets at least one of those.

None of it is guaranteed. Clinical trials fail more often than they succeed. Continuum and Navitor are proof.

The thesis I keep coming back to: if even a fraction of this science delivers, the people paying attention now are the ones who benefit first. Not because investing gives you access to experimental drugs. It does not. But because tracking the science closely means you understand what is coming, what is working, and what the data says versus what the headlines say. You make better decisions about your own health with your own doctors.

I spent 24 years watching people at CuraDebt fight to build financial security. Some of them succeeded. And then their bodies gave out. The money was there but the years were not.

I'm 52. I track my biomarkers. I optimize my protocols. I pay close attention to clinical data from companies like these, not because I own their stock, but because their science may determine whether I get 20 more good years or 50.

That is the dual return. One hypothetical, measured in multiples. The other real, measured in years. Neither is guaranteed.

This section reflects my personal perspective. It is not investment advice or medical advice. No claim is made that any therapy discussed will extend lifespan or healthspan. Consult a licensed physician regarding health decisions.

Continuum, 0.0x. Total loss. $200K. Scored 3.8, right at the floor. No clinical data.

Navitor, 0.3-0.8x. Real loss. Phase 2 failure. The mTOR thesis is sound but execution did not deliver. Anakuria spinout to Janssen recovered some value. Not enough.

Turn.bio, 1.1-2.6x. Klotho LOI fell through. Company remains independent with some value from the HanAll license. Not a loss, but not what it should have been.

BioAge, 1.5-3.1x (pivot hold) or 0.6-1.0x (strict exit). Azelaprag failed. Pivot Re-Evaluation Protocol applied. BGE-102 re-scored at 4.0 with Phase 1 data and Novartis validation. Held at 50%. Strict exit would have produced a near-total loss at ~$3-5/share.

The most important gates are not about picking winners. They are about knowing when to sell.

Every position is set at entry and held until an exit or a sell trigger fires. No follow-ons.

Milestone tracking: IND filing, Phase 1 safety, Phase 2 efficacy, pharma partnerships, pivotal trial initiation. Each increases conviction. Conviction without sell discipline is just hope.

Mandatory sell triggers (cut 50% immediately): safety signal, cash below 9 months with no bridge, competitor reports positive Phase 2 in same mechanism, CEO/CSO departure with no successor in 30 days.

Full exit triggers: failed primary endpoint, negative pre-IND/Type B meeting with re-score below veto, company runs out of cash.

This protocol exists because lead programs fail, and the question is whether the company behind the program still has value. The protocol is not discretionary. It is a four-gate binary test. All four criteria must be met or the position exits in full.

Trigger: Lead program fails a primary efficacy endpoint, activating a full exit signal under Gate 25.

Evaluation window: 90 days from the date of failure.

Four required criteria (all must be met):

If all four are met: The backup program is scored through the full 25-gate framework as if it were a new investment at current market price. If the backup scores 3.8 or above, the position is held at 50% of original size. If below 3.8, full exit.

If any criterion is not met: Full exit. No exceptions.

Reporting: When this protocol applies, both interpretations (strict exit and pivot hold) are reported with full return math for each.

Application in this portfolio: BioAge (BIOA) is the only company where this protocol was triggered. Azelaprag failed Phase 2 in November 2024. BGE-102 met all four criteria: Phase 1 human data showing 90-98% IL-1B suppression, 18+ months cash, no leadership departure, Novartis $550M collaboration signed post-failure. BGE-102 re-scored at 4.0. Position held at 50%.

Public company rule: Sell 50% on positive Phase 2 data, hold the rest with 25% trailing stop. No Phase 3 or M&A within 18 months of positive Phase 2? Full exit.

The framework does not prevent failure. It prevents holding through failure.

The last 10 years happened in specific conditions. Longevity biotech was new, misunderstood, underfunded. The pricing gaps were wide because the market was not paying attention.

That is changing. More capital flowing in. Entry valuations rising. The specific opportunities will not look like Carmot or Verve. But the pattern, mispriced science eventually finding its strategic acquirer, is worth studying.

Future investment results in longevity biotech could be materially worse than the hypothetical results in this article. Higher entry valuations, increased competition, and changing regulatory environments may reduce or eliminate the pricing gaps that existed in 2015-2025.

Eric Pemper Founder, EverLife Capital

No Investment Advice. EverLife Capital is an independent educational publication. I am not a registered investment advisor, broker-dealer, or fiduciary. I hold no securities licenses. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed financial advisor before making any investment decision.

Hypothetical Performance. All returns describe a hypothetical paper exercise. No real capital was invested. No trades occurred. Results carry inherent limitations including hindsight bias and the absence of actual risk (CFTC Rule 4.41). The ~4.2x return is not representative of typical results. The majority of early-stage biotech startups fail, resulting in 100% loss of capital.

Backtesting. The 25-Gate Framework was developed and refined using the same data it evaluates. Its apparent performance is a product of historical alignment, not forward-looking validation. This is backtesting and carries the standard limitations described in the Methodology Bias section above.

Accredited Investor Access. Approximately 95% of entries involve early-stage private rounds legally restricted to accredited investors under SEC Rule 501 of Regulation D. This generally requires annual income exceeding $200,000 ($300,000 jointly) or net worth exceeding $1 million (excluding primary residence). Even qualifying investors may not have access to specific rounds due to allocation constraints.

Illiquidity. Nine companies remain private. Estimated values are based on implied post-money from the last priced round and do not account for liquidation preferences, participation rights, or transaction costs. There is no secondary market. Paper gains are theoretical until an exit occurs. Early-stage common equity holders often receive less than implied ownership percentages suggest due to senior liquidation preferences held by later-stage institutional investors.

Retroactive Analysis. This framework was applied retroactively with knowledge of outcomes. Forward-looking application may produce materially different results.

Conflicts of Interest. I hold equity in Yuva Biosciences and Repair Biotechnologies (neither in the hypothetical portfolio). I hold long positions in DNLI, BIOA, and 3696.HK. I derive revenue from subscriptions. Company inclusion was determined solely by the framework.

Compliance. No paid endorsements or affiliate arrangements (FTC 16 CFR Part 255). Not an offer to sell or solicitation to buy securities (SEC). References to government agencies do not imply endorsement.

Copyright 2026 EverLife Capital. All rights reserved.